REGISTERED NUMBER: 11892521 (England and Wales)

AMENDED

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021 FOR CAMBRIDGE MOLECULAR LTD

- These replace the original accounts
 - Are now the statutory accounts
- Are prepared as they were at the date of the original accounts

AA86R7ØH
A05 06/07/2021 #105
COMPANIES HOUSE

CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

	Page
Company Information	1
Statement of Income and Retained Earnings	2
Balance Sheet	. 3
Notes to the Financial Statements	5

COMPANY INFORMATION FOR THE YEAR ENDED 31 MARCH 2021

DIRECTORS:

D Kirpichenko

G P Lewy

REGISTERED OFFICE:

The Bradfield Centre 184 Cambridge Scien

Milton Road Cambridge CB4 0GA

REGISTERED NUMBER:

11892521 (England and Wales)

ACCOUNTANTS:

Crowe U.K. LLP

Chartered Accountants Black Country House Rounds Green Road

Oldbury

West Midlands B69 2DG

STATEMENT OF INCOME AND RETAINED EARNINGS FOR THE YEAR ENDED 31 MARCH 2021

	Year Ended	Period 19.3.19 to
	31.3.21	31.3.20
	£	£
TURNOVER	17,488	10,380
Administrative expenses	4,924	54,706
OPERATING PROFIT/(LOSS) and PROFIT/(LOSS) BEFORE TAXATION	12,564	(44,326)
Tax on profit/(loss)	<u> </u>	·
PROFIT/(LOSS) FOR THE FINANCIAL YEAR	12,564	(44,326)
Retained earnings at beginning of year	(44,326)	-
		-
RETAINED EARNINGS AT END OF YEAR	(31,762)	(44,326)

CAMBRIDGE MOLECULAR LTD (REGISTERED NUMBER: 11892521)

BALANCE SHEET 31 MARCH 2021

		202	1	202	0
	Notes	£	£	£	£
FIXED ASSETS Tangible assets	4		1,741		2,322
CURRENT ASSETS Cash at bank		17,565		2,950	
CREDITORS Amounts falling due within or	ne year 5	50,968		49,498	·
NET CURRENT LIABILITIES	S .		(33,403)		(46,548)
TOTAL ASSETS LESS CUR LIABILITIES	RENT		(31,662)		(44,226)
CAPITAL AND RESERVES Called up share capital Retained earnings			100 (31,762)		100 (44,326)
			(31,662)		(44,226)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2021 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CAMBRIDGE MOLECULAR LTD (REGISTERED NUMBER: 11892521)

BALANCE SHEET - continued 31 MARCH 2021

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on ...O.2_/_O.7_/_2_O.2_1. and were signed on its behalf by:

D Kirpichenk Director

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

1. STATUTORY INFORMATION

Cambridge Molecular Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

On 3 June 2021, the company changed its name from Sublime Biotechnologies Ltd.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 20% on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2021

3. **EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 2 (2020 - 3).

4. TANGIBLE FIXED ASSETS

••			Plant and machinery etc £
	COST		-
	At 1 April 2020		
	and 31 March 2021		2,903
	DEPRECIATION		
	At 1 April 2020		581
	Charge for year		581
	At 31 March 2021		1,162
	NET BOOK VALUE		
	At 31 March 2021		1,741
	At 31 March 2020		2,322
5.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
		2021	2020
		£	£
	Taxation and social security	-	5,852
	Other creditors	50,968	43,646
		50,968	49,498